Salicylalazine: A novel therapeutic agent targeting TLR4/NLRP3/GSDMD-mediated pyroptosis in rheumatoid arthritis
In a nutshell, SAZ achieved significant anti-arthritic benefits, most likely via the modulation of the TLR4/NLRP3/GSDMD-mediated pyroptosis pathway, lowering oxidative stress, and improvement of clinical findings. Taking into consideration these findings, it seems that SAZ has the potential to be an effective treatment alternative for the management of arthritis.
Authors
- Shaimaa R. Ahmed (ORCID: https://orcid.org/0000-0003-3336-4540)
- Fakhria A. Al‐Joufi
- Ambreen Malik Uttra (ORCID: https://orcid.org/0000-0002-4800-4882)
- Sumera Qasim (ORCID: https://orcid.org/0000-0002-6082-6889)
- Hafiza Sara Afzal
Institutions
- University of Sargodha (PK)
- Jouf University (SA)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1016/j.intimp.2024.113778
- Citations
- 7
- Primary Topic
- Pediatric health and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 5.21